Status:
COMPLETED
TURN-COVID Biobank: The Dutch Cohort Study for the Evaluation of the Use of Neutralizing Monoclonal Antibodies and Other Antiviral Agents Against SARS-CoV-2
Lead Sponsor:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Conditions:
COVID-19
Eligibility:
All Genders
18+ years
Brief Summary
Novel antiviral drugs can mark a turning point in the prevention and treatment of patients with Covid-19. Recently, several independent large phase-III RCTs have shown that the intravenous administrat...
Detailed Description
2\. INTRODUCTION AND RATIONALE New SARS-CoV-2 specific monoclonal antibodiestherapies From the beginning of the worldwide pandemic till now no effective specific anti- SARS-CoV-2 treatment was availab...
Eligibility Criteria
Inclusion
- All patients that are treated with neutralizing monoclonal SARS-CoV-2 antibodies or with small-molecules for Covid-19 as standard of care.
- Patients have to be aged ≥ 18 y.
Exclusion
- No informed consent is provided by the patient or by his/her legal representative
- Patients not suitable to fulfil study procedures
Key Trial Info
Start Date :
December 14 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2025
Estimated Enrollment :
1178 Patients enrolled
Trial Details
Trial ID
NCT05195060
Start Date
December 14 2021
End Date
September 1 2025
Last Update
December 16 2025
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Amsterdam University Medical centre - VUMC
Amsterdam, North Holland, Netherlands, 1081 HV
2
Amsterdam University Medical Centre
Amsterdam, North Holland, Netherlands, 1105 AZ
3
Leiden universitair medisch centrum
Leiden, Netherlands, 2333ZA
4
Radboud Universitair Medisch Centrum
Nijmegen, Netherlands, 6525GA